Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal–oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of k...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-06, Vol.24 (25), p.5300-5310
Main Authors: Mitchell, Leslie Ann, Joseph, Aviva, Kedar, Eli, Barenholz, Yechezkel, Galun, Eitan
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Animals
Antigens
Applied microbiology
Biological and medical sciences
Cationic lipid delivery system
Cations
Cholesterol
Cholesterol - administration & dosage
CpG motifs
Female
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis A
Hepatitis A - immunology
Hepatitis A - prevention & control
Hepatitis A Antibodies - blood
Hepatitis A Vaccines - administration & dosage
Hepatitis A Vaccines - immunology
Hepatitis A virus
Hepatitis A virus - immunology
Human viral diseases
Immune system
Immunity, Mucosal
Immunization
Infections
Infectious diseases
Lipids
Liposomes - administration & dosage
Medical sciences
Mice
Mice, Inbred BALB C
Microbiology
Oligodeoxyribonucleotides - administration & dosage
Sphingolipids - administration & dosage
Synthetic ODN adjuvants
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal–oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synthetic oligodeoxynucleotides (ODNs) containing CpG sequences, and a novel polycationic sphingolipid (CCS)/cholesterol liposomal delivery system, markedly enhances the HAV-specific antibody response at the intestinal interface, particularly when delivered intrarectally or intranasally, to Balb/c mice at low HAV doses. A mucosally delivered, antigen-sparing HAV vaccine that is easily administered without specialized equipment or personnel, is an attractive alternative for facilitating mass immunization in hepatitis A outbreaks.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.04.015